Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH – Business Wire (press release)
Endpoints News |
Juno Therapeutics to Highlight New Advances in CD19- and BCMA-Targeted CAR T Therapy at ASH
Business Wire (press release) “The presentations at ASH will showcase promising data coming from our pipeline of CD19- and BMCA-directed CAR T cell product candidates,” said Sunil Agarwal, M.D., Juno's President of Research and Development. "Results from the ongoing … Head-To-Head Contrast: Juno Therapeutics (NASDAQ:JUNO) versus Its Rivals |
